Page last updated: 2024-12-07
allotetrahydrocortisol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
allotetrahydrocortisol: RN given refers to (3alpha,5alpha,11beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 92748 |
| CHEBI ID | 89627 |
| SCHEMBL ID | 5609666 |
| MeSH ID | M0049046 |
Synonyms (72)
| Synonym |
|---|
| allopregnane-3.alpha.,17.alpha.,21-tetrol-20-one |
| compound f, allotetrahydro- |
| wintersteiner's compound d |
| allocortisol, tetrahydro- |
| nsc86469 |
| .alpha.-thf |
| nsc-86469 |
| 302-91-0 |
| allotetrahydrocortisol |
| cortisol, allotetrahydro- |
| athf |
| 5.alpha.-tetrahydrocortisol |
| 3.alpha.,5.alpha.-tetrahydrocortisol |
| allo-tetrahydrocortisol |
| pregnan-20-one,11,17,21-tetrahydroxy-, (3.alpha.,5.alpha.,11.beta.)- |
| allotetrahydrocompound f |
| kendall's compound c |
| tetrahydroallocortisol |
| 5.alpha.-pregnan-20-one,11.beta.,17,21-tetrahydroxy- |
| allo-3.alpha.-tetrahydrocortisol |
| reichstein's substance c |
| 5a-tetrahydrocortisol |
| LMST02030200 |
| 2-hydroxy-1-[(3r,5s,8s,9s,10s,11s,13s,14s,17r)-3,11,17-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone |
| allopregnane-3alpha,11beta,17alpha,21-tetrol-20-one |
| 5alpha-tetrahydrocortisol |
| pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3alpha,5alpha,11beta)- |
| 3-alpha,11-beta,17-alpha,21-tetrahydroxy-5-alpha-pregnan-20-one |
| a30u7u312e , |
| 3alpha,5alpha-tetrahydrocortisol |
| allo-3alpha-tetrahydrocortisol |
| alpha-thf |
| nsc 86469 |
| einecs 206-131-1 |
| 5alpha-pregnan-20-one, 3alpha,11beta,17,21-tetrahydroxy- |
| unii-a30u7u312e |
| allo-3|a-tetrahydro cortisol |
| allopregnane-3.alpha.,11.beta.,17.alpha.,21-tetrol-20-one |
| pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.alpha.,11.beta.)- |
| (3.alpha.,5.alpha.,11.beta.)-3,11,17,21-tetrahydroxypregnan-20-one |
| 3.alpha.-allotetrahydrocortisol |
| 3.alpha.,11.beta.,17,21-tetrahydroxy-20-oxo-5.alpha.-pregnane |
| 3.alpha.,11.beta.,17,21-tetrahydroxy-5.alpha.-pregnan-20-one |
| 17-(1-keto-2-hydroxyethyl)androstane-3,11,17-triol |
| allopregnane-3.alpha.,11.beta.,17.alpha.,21-tetrol-20-one [mi] |
| SCHEMBL5609666 |
| CHEBI:89627 |
| AODPIQQILQLWGS-FDSHTENPSA-N |
| 5a-pregnane-3a,11b,17a,21-tetrol-20-one |
| allotetrahydro-cortisol |
| tetrahydro-allocortisol |
| 5a-pregnane-3a,11b,17a,21-tetraol-20-one |
| allo-3a-tetrahydrocortisol |
| 3alpha, 5alpha-tetrahydrocortisol |
| allotetrahydro-compound f |
| 3a,11b,17,21-tetrahydroxy-5a-pregnan-20-one |
| allopregnane-3a,11b,21-tetrol-20-one |
| 3a,11b,17a,21-tetrahydroxy-5a-pregnan-20-one |
| a-thf |
| 3a,5a-tetrahydrocortisol |
| allopregnane-3a,11b,17a,21-tetrol-20-one |
| 3a-allotetrahydrocortisol |
| Q27161825 |
| 3,11,17,21-tetrahydroxypregnan-20-one |
| allo-3alpha-tetrahydro cortisol |
| DTXSID80861575 |
| 2-hydroxy-1-((3r,8s,9s,10s,11s,13s,14s,17r)-3,11,17-trihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethanone |
| HY-113215 |
| CS-0059329 |
| allo-3?-tetrahydro cortisol |
| PD126220 |
| AKOS040740675 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The aim of this study was to determine whether in major depression changes in the activity patterns of local modulators of glucocorticoid action might contribute to an increase in cortisol bioavailability and if they change during antidepressant treatment and clinical response." | ( Cortisol metabolism in depressed patients and healthy controls. Deuschle, M; Frankhauser, P; Gilles, M; Hamann, B; Kopf, D; Lederbogen, F; Lewicka, S; Onken, V; Römer, B; Schilling, C, 2009) | 0.35 |
| " These changes suggest an increase in cortisol bioavailability within tissues." | ( Cortisol metabolism in depressed patients and healthy controls. Deuschle, M; Frankhauser, P; Gilles, M; Hamann, B; Kopf, D; Lederbogen, F; Lewicka, S; Onken, V; Römer, B; Schilling, C, 2009) | 0.35 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| corticosteroid hormone | Any of a class of steroid hormones that are produced in the adrenal cortex. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Pathways (1)
| Pathway | Proteins | Compounds |
|---|---|---|
| Glucocorticoid biosynthesis | 14 | 11 |
Research
Studies (38)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 12 (31.58) | 18.7374 |
| 1990's | 7 (18.42) | 18.2507 |
| 2000's | 10 (26.32) | 29.6817 |
| 2010's | 9 (23.68) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 10.73
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.73) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (2.56%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 5 (12.82%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 33 (84.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||